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Abstract
The primary pathology of Hirschsprung’s disease (HSCR, colon aganglionosis) is the absence of ganglia in variable lengths of
the hindgut, resulting in functional obstruction. HSCR is attributed to a failure of migration of the enteric ganglion
precursors along the developing gut. RET is a key regulator of the development of the enteric nervous system (ENS) and the
major HSCR-causing gene. Yet the reduced penetrance of RET DNA HSCR-associated variants together with the phenotypic
variability suggest the involvement of additional genes in the disease. Through a genome-wide association study, we
uncovered a ,350 kb HSCR-associated region encompassing part of the neuregulin-1 gene (NRG1). To identify the causal
NRG1 variants contributing to HSCR, we genotyped 243 SNPs variants on 343 ethnic Chinese HSCR patients and 359
controls. Genotype analysis coupled with imputation narrowed down the HSCR-associated region to 21 kb, with four of the
most associated SNPs (rs10088313, rs10094655, rs4624987, and rs3884552) mapping to the NRG1 promoter. We
investigated whether there was correlation between the genotype at the rs10088313 locus and the amount of NRG1
expressed in human gut tissues (40 patients and 21 controls) and found differences in expression as a function of genotype.
We also found significant differences in NRG1 expression levels between diseased and control individuals bearing the same
rs10088313 risk genotype. This indicates that the effects of NRG1 common variants are likely to depend on other alleles or
epigenetic factors present in the patients and would account for the variability in the genetic predisposition to HSCR.
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Introduction
Hirschsprung’s disease (HSCR, aganglionic megacolon) is a
congenital disorder of the enteric nervous system (ENS) char-
acterised by the absence of enteric ganglia along a variable length
of the intestine. There is significant ethnic variation in the
incidence of the disease, and it is most often found among Asians
(2.8 per 10,000 live births)[1,2]. Non-familial HSCR has a
complex pattern of inheritance and manifests with low, sex-
dependent penetrance and variability in the length of the
aganglionic segment, according to which patients are classified
into short segment (S-HSCR; 80%), long segment (L-HSCR;
15%), and total colonic aganglionosis (TCA; 5%). The male:fe-
male ratio is <4:1 among S-HSCR patients and <1:1 among L-
HSCR patients. The recurrence risk to sibs of S-HSCR probands
ranges between 1.5% and 3.3%, while risk to sibs of L-HSCR
probands varies from 2.9% to 17.6%[1].
The RET gene, encoding a tyrosine-kinase receptor, is the
major HSCR causing gene[3,4] and its expression is crucial for the
development of the enteric ganglia. Mutations in the coding
sequence (CDS) of RET account for up to 50% of the familial cases
and between 15%–20% of the sporadic cases[5]. Other HSCR
genes identified so far mainly code for protein members of
interrelated signalling pathways involved in the development of
enteric ganglia: RET, endothelin receptor B (EDNRB), and the
transcriptional regulator SOX10. Yet, mutations in genes other
than RET account for only 7% of the cases[6,7,8,9,10,11,12,13].
Despite the importance of RET, additional genes (acting either in
conjunction with or independently from RET) are necessary to
explain not only the disease incidence but also its complex pattern
of inheritance.
Through a genome-wide association study (GWAS) on Chinese
individuals we identified the association of a 350 kb genomic
region encompassing intron 1 of the NRG1 gene with Hirsch-
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16181
sprung’s disease[14]. Within the NRG1 region, the strongest
overall associations were found for two SNPs located in intron 1 of
the neuregulin1 gene (NRG1) on 8p12, with rs16879552 and
rs7835688 (underlined throughout the text; supplementary Figure
S1) yielding odds ratios of 1.68 [CI95%:(1.40,2.00),
p=1.8061028] and 1.98 [CI95%:(1.59,2.47), p=1.1261029],
respectively, for the heterozygous risk genotypes under an additive
model. NRG1 plays an important role in ENS development and
maintenance[15,16,17,18].
As these intron 1 NRG1 HSCR-associated SNPs are not
predicted to functionally affect the gene, we hypothesized that
these loci are in linkage disequilibrium (LD) with a functional
variant(s) not covered by the 500K Affymetrix chips used in our
initial GWAS. To find those functional variant(s), we increased the
genotype density within the region by genotyping 243 SNPs in 343
HSCR Chinese HSCR patients and 380 Chinese controls.
Genotype imputation was used to further increase the SNPs
density. As the NRG1 HSCR-associated region encompasses
regulatory regions, we hypothesized that NRG1 SNPs could affect
HSCR susceptibility by altering NRG1 expression. Thus, the
difference between NRG1 expression levels in gut tissues of affected
and non-affected individuals was tested, along with the relation-
ship of expression with NRG1 genotype.
Results and Discussion
Fine mapping implicates the NRG1 promoter in HSCR
susceptibility
Fine mapping of NRG1 was carried out by genotyping
additional SNPs within the region delimited by the upstream
and downstream recombination hot spots. We found 9 SNPs
(‘‘typed’’ in Table 1) more significantly associated with HSCR
than rs7835688 (initially discovered in the GWAS; p=5.9261024;
OR=1.73 and 95% CI= 1.28–2.32 in this set) and one SNP with
a p-value lower than that of the also GWAS identified rs16879552
(p=8.9961025; OR=1.63 and 95% CI= 1.29–2.07; also in this
set).
The SNP displaying the strongest association (rs10088313; in
bold face in Table 1) mapped to the promoter region of most
NRG1 isoforms, (except GGF2, associated with Schizophre-
nia[19]), and had the strongest LD (r2 = 0.84) with rs16879552.
Other top SNPs were also in moderate to high LD with the
previously GWAS-implicated SNPs (rs7835688 and rs16879552)
(Figure 1, upper panel).
We next tried to refine our findings by imputing un-typed
SNP allelic dosage using MACH. Imputation (based on HapMap
Phase II haplotypes) nominated three additional HSCR-associated
SNPs, rs10094655, rs4624987 and rs3884552, with highly similar
level of association as rs16879552. In particular, rs3884552
displayed the highest significance level among all (Table 1). These
markers fall again into the promoter of NRG1, about 10 kb
upstream of rs16879552. Together with rs10088313, all five SNPs
(rs10088313, rs10094655, rs4624987, rs3884552, and rs16879552)
are highly correlated and have a similar MAF in both cases and
controls. Beyond the region set by rs10088313 and rs16879552,
we did not found any SNPs of similar levels of LD and signi-
ficance. Thus, fine mapping coupled with imputation identified 5
highly associated SNPs (highlighted in grey in Table 1) narrowing-
down the NRG1 associated region from 350 kb to 21.155 kb
(Figure 1, lower panel). Haplotype analysis did not result in any
haplotype appreciably more associated with HSCR than any
single SNP.
As further genotyping and statistical genetic analysis of these 5
equally associated SNPs in an expanded sample would not help
discern causality among these linked SNPs, we resorted to
comparative genomics for the identification of conserved regula-
tory regions overlapping/neighbouring these loci as this would
point at the functional SNP. Two conserved regions overlapping
the two associated SNPs, rs10088313 and rs4624987 respectively,
were observed (see Supplementary Figure S2). In particular, the
region encompassing rs4624987 associates with signals of
H3K4me1 and H3K27Ac chromatin activity, suggesting the
presence of an enhancer. Importantly, rs4624987 falls in the
vicinity of a transcription factor binding site (TFBS) for the
transcription factor (TF) EVI1 (PhastCon 28-way score .0.93).
No other described regulatory elements were identified. Even
though the TFBS for EVI1 does not overlapped with rs4624987,
the SNP associated allele might introduce a new site or reduce
access to the predicted site located only a few base-pairs away.
According to the literature reviewed, mice homozygous for
targeted null Evi1 mutations are embryonic lethal and are
characterized by widespread hypocellularity and poor/disrupted
development of the cardiovascular and neural crest-derived
cells[20].
As current data do not allow us to single out any of the four
SNPs, we would argue that, most likely, they collectively represent
a single signal of association and the lesser associated SNPs in the
region are the aftermath of the indirect association. The fine-
mapping of this NRG1 region may not been effective due to the
high correlation among SNPs. Yet, the 350 kb region has been
narrowed-down to a 21 kb region within which the most HSCR-
associated NRG1 SNPs point at the NRG1 promoter as the culprit.
Plausibly, the HSCR-associated alleles are bound to alter the
regulation of NRG1 transcription and confer susceptibility to
HSCR by affecting, in turn, the role of NRG1 signalling during
ENS development.
HSCR-associated SNPs and NRG1 expression levels in
human gut. If the NRG1 HSCR-associated SNPs identified in
the promoter are functional (or in LD with a causal variant not
discerned due to LD), they are likely to affect the gene expression.
Thus, we next investigated whether there was a correlation
between the genotypes of the NRG1 HSCR-associated SNPs and
the levels of expression for this gene in human gut. Even though
the causal variant cannot be pinpointed due to the high LD in the
narrowed fine-mapped region, we assumed that the genotypes of
the typed rs10088313 would represent those of the causal variant.
Due to alternative splicing, the NRG1 gene generates at least 3
main types (Type I, II and III) of proteins and at least 31
isoforms[19]. As each NRG1 type may have a different tissue-
specific function, we assessed by RT-PCR which of the three main
NRG1 types[15] was mainly expressed in human gut (data not
shown). We detected expression of NRG1 Type I and vestigial
expression of NRG1 type III (Sensory and Motor-neuron Derived
Factor; SMDF; NM_013959.2). We did not detect expression of
NRG1 type II. The feeble expression of NRG1 Type III detected
in some samples may be due to the peripheral nervous system
innervations of the gut, which is independent of the ENS.
In order to assess the effect of the NRG1HSCR-associated SNPs
on the expression of NRG1 type I in human gut, we used
quantitative real-time PCR. We would also like to point out that as
NRG1 is expressed in both intestinal mucosa and enteric
ganglia[14], we did not discriminate between the different gut
cellular types and assumed that the effect of the NRG1 regulatory
SNPs would indiscriminately affect the total amount of NRG1
expressed in the gut.
The overall NRG1 expression in gut did not differ between
patients and controls (F = 2.18, p=0.15, two way ANOVA) as well
as among genotypes for the combined samples (F = 0.29, p=0.75).
Fine Mapping of NRG1
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Significant interaction between genotype and case-control status
(F = 5.54, p=0.0064) was found, indicating that the relationship
between genotype and expression level differs between cases and
controls. When both groups (cases and controls) were stratified
according to the rs10088313 genotypes (GG, GT, TT; risk allele
in bold), post hoc pair-wise t-tests resulted in statistically significant
differences among the three genotypes only within the control
group (Figure 2). In this group, the highest NRG1 expression levels
were observed in individuals with the GG (risk) genotype and the
lowest in individuals with the TT genotype. Furthermore, GG in
controls shows higher expression than GG in cases. These data
suggest that the NRG1 risk allele has opposite effects on patients
compared to controls. This may be explained by an additional
susceptibility factor/s (mainly present in the HSCR group)
interfering with the role played by rs10088313 in NRG1
regulation. This allows us to hypothesize the presence of trans-
acting elements that interact with NRG1 regulatory sites
modulating their genetic effect on NRG1 transcription. In this
context, patients’ specific mutations or polymorphisms in the gene
encoding the predicted EVI-1 TF could account for the different
effects observed for the rs10088313 G allele. Another attractive
hypothesis would be that the effect of the rs10088313 G allele was
dependant on the RET risk alleles. This would be backed-up by
our finding of genetic interaction between the RET rs2435357 (C/
T) T risk allele and the NRG1 risk alleles identified in our
GWAS[14,21]. Importantly, while most of the controls with
rs10088313 GG genotypes (N=6) did not harbour the RET risk
allele T (5 were CC and 1 CT for rs2435357), most patients with
rs10088313 GG genotype (N= 11) had the RET risk allele T (7
were TT and 2 CT for rs2435357). We previously showed that this
RET rs2435357T HSCR risk allele is associated with reduction of
RET gene expression in gut tissues[22]. Thus, stratified analysis of
NRG1 expression according to the RET rs2435357 genotypes
would have helped elucidate if the reduction in RET expression
relates to that of NRG1 and could perhaps account for the
differences encountered in NRG1 expression between patients and
controls with the same NRG1 genotype. We could not perform
such stratified analysis as the sample size is not large enough and
because the high frequency of the RET risk in the Chinese
population prevents us from obtaining a large enough represen-
tation of all RET genotypes.
We have recently demonstrated that the RET rs2435357 T risk
allele disrupts a SOX10 binding site that compromises RET
transactivation[23] SOX10 is also known to regulate the expres-
sion of NRG1 receptor ErbB3 in neural crest cell receptors[15]
Though the link between RET and NRG1 signalling in the
development of the ENS is still to be elucidated our data suggests
that NRG1 is player in the signaling network implicated in ENS
development and maintenance and that may genetically and
biologically interact with members of the RET signalling pathway
during the ENS development. Biological interaction between RET
and NRG1 signaling has been reported and linked to the survival
and maintenance of the peripheral nervous system, where injury-
induced expression of the RET ligand GDNF by non-myelinating
Schwann cells is ErbB dependent[24].
We suspect that our expression data may be reflecting the result
of the genetic NRG1-RET interaction previously described[14].
Somehow comparable findings have been reported in a study on
NRG1 expression in post-mortem human brain samples of
schizophrenic patients and control individuals where NRG1
expression levels differ between patients and controls for a given
NRG1 schizophrenia susceptibility SNP genotype[25]. Collectively,
Table 1. Fine mapping association results of NRG1 SNPs using logistic regression on MACH-imputed allelic dosage
MAFa,,b Allelec
Before
imputation Association values after imputation
SNP Position Cases Controls Minor Major Type P OR (95%CI) P
rs16879425 32426748 0.44 0.34 A C typed 2.29E-04 1.57 (1.23,1.99) 2.21E-04
rs10954845 32439384 0.35 0.25 A G typed 2.57E-04 1.59 (1.24,2.05) 3.29E-04
rs4422736 32490062 0.45 0.35 C T typed 4.00E-04 1.54 (1.20,1.96) 4.00E-04
rs10113578 32503670 0.51 0.40 G A imputed NA 1.53 (1.22,1.94) 3.18E-04
rs10088313 32509603 0.52 0.40 G T typed 6.71E-05 1.60 (1.27,2.02) 6.71E-05
rs10107065 32510100 0.52 0.40 A G imputed NA 1.60 (1.27,2.01) 7.65E-05
rs10113593 32510900 0.51 0.40 T C typed 2.18-04 1.55 (1.23,1.96) 2.04E-04
rs10094655 32513689 0.52 0.39 T A imputed NA 1.63 (1.29,2.05) 4.27E-05
rs4624987 32516246 0.52 0.40 G A imputed NA 1.62 (1.29,2.05) 4.69E-05
rs3884552 32519399 0.53 0.42 C T imputed NA 1.65 (1.30,2.09) 4.13E-05
rs7826312 32519657 0.24 0.14 C T typed 3.22E-04 1.77 (1.30,2.41) 3.22E-04
rs3802159 32524243 0.51 0.39 G C typed 1.25E-04 NA NA NA
rs7834206 32525690 0.27 0.16 A C typed 2.27E-04 NA NA NA
rs16879552 32530758 0.51 0.38 C T typed 8.99E-05 1.63 (1.29,2.07) 4.19E-05
rs7835688 32531041 0.26 0.15 C G typed 5.92E-04 1.73 (1.28,2.32) 3.30E-04
rs16879576 32560777 0.51 0.41 C A imputed NA 1.57 (1.24,1.99) 1.87E-04
rs12680129 32562687 0.51 0.41 A G typed 1.86E-04 1.57 (1.24,1.98) 1.83E-04
Only SNPs with P-value lower than either or both of the 2 previously implicated SNPs (rs16879552 and rs7835688) are shown;
a: minor allele frequency; underlined: SNPs found associated in the previously reported GWAS.
b: frequencies reported for imputed alleles (except for rs3802159 and rs7834206);
c: minor and major alleles in patients and controls combined; in bold genotyped SNP with the lowest p association value.
doi:10.1371/journal.pone.0016181.t001
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these findings warrant further study on NRG1 regulation and its
implication in diseases.
This expression study has limitations, some of which cannot be
overcome. Firstly, the gut of newborn patients is in an advanced
developmental stage (although not fully mature). Thus our analysis
does not mimic the expression of NRG1 during the early
developmental stages of the human gut, when expression patterns
of other genes may be different. For obvious reasons, this cannot
be surmounted. Secondly, also for obvious reasons, it is not
possible to obtain gut tissue samples from controls, requiring us to
use samples from individuals who underwent gut biopsy for other
motives than HSCR. Thirdly, the limited sample size is hampering
the expression study. Again, it is difficult to obtain a balanced
representation of all NRG1 SNP genotypes and a desirable number
of gut tissues from affected and non-affected individuals.
We conclude that NRG1 regulatory SNPs may confer an
increased risk of HSCR by interfering with the normal NRG1
expression in human developing gut and their effect is likely to
depend on the genetic background of the individual, most likely
DNA alterations on trans-acting regulatory proteins expressed in
the developing gut in a time-specific manner or in other main
HSCR genes such as RET. Why and how altered NRG1 expression
may contribute to HSCR is yet to be learned.
Materials and Methods
Ethics Statement
At recruitment, informed consent was obtained from each
subject. This study was approved by the institutional review board
of the University of Hong Kong (UW 03-227 T/227).
Subjects
A total 343 ethnic Chinese patients diagnosed with sporadic
HSCRwere included for genotyping. Of those, 258HSCRhad been
included in our previous GWAS[14] and 177 in the fine mapping
of the 9q31 HSCR susceptibility locus[26]. The characteristics
of the patients are summarized in supplementary Table S1.
Control individuals were obtained from the blood bank of the
Hong Kong Red Cross. We included a total of 359 ethnic Chinese
subjects without a diagnosis of HSCR.
Gut tissues were collected from 40 HSCR patients (subset of the
343 individuals genotyped) and 21 non-HSCR patients who had
undergone colon surgery for reasons other than HSCR. For the 21
non-HSCR patients (12 affected with imperforate anus; 7 with
necrotizing enterocolitis and 2 with mesenteric cysts), tissues were
obtained from at least 2 cm away from the margin of the diseased
bowel.
The HSCR diagnosis was histologically confirmed with either
biopsy or surgical resection material for absence of enteric plexuses.
SNP selection. Following the identification of the NRG1
rs16879552 and rs7835688 HSCR-associated SNPs and the
delimitation of the 350 kb HSCR-associated region (chromo-
some 8:32.235–32.575 Mb; hg18) as originally described, we
proceeded with fine-mapping.
The 350 kb region is flanked by two major recombination
hotspots (A: 32.235–32.245 Mb and C:32.565–32.575 Mb). A
close-up look at the recombination rate within the region
(downloaded from HapMap Phase II database) revealed an
additional hotspot (B: 32.395–32.405 Mb) that disrupts slightly
the LD of the main haplotype block (Supplementary Figure S1).
LD was found to be stronger in the region flanked by hotspots B
and C. This B–C region spans from the 59 UTR to exon 2 of the
NRG1 isoforms (except for isoform GGF-2 -Glial Growth Factor-;
NM_013962.2) and includes mostly non-coding sequence DNA
containing conserved noncoding elements (CNEs) which are likely
Figure 1. Fine mapping association results of NRG1 SNPs.
Association results shown before (upper panel) and after imputation
(lower panel). Diamonds and circles indicate genotyped and imputed
SNPs respectively. Colour gradient (red r2 = 1 to white r2 = 0) marks the
LD of the SNPs with rs10088313, except green for rs7835688, dark green
for rs16879552 and blue for itself; grey indicates no information on LD.
The 21 kb region we narrowed down to is highlighted in pink. The fine-
scale recombination rate across the region is represented by the light-
blue line. Green lines symbolize a schematic representation of the NRG1
isoforms overlapping the associated region. The bottom green line
represents the GGF2 isoform associated with schizophrenia that
expands 900 kb upstream the transcription start site for the rest of
NRG1 isoforms.
doi:10.1371/journal.pone.0016181.g001
Figure 2. NRG1 expression in human gut tissues. Quantitative RT-
PCR analysis of log-transformed expression ratio of NRG1 to 18S in the
colon tissues from the normal portions of HSCR patients and non-HSCR
patients stratified according to the rs10088313 (G/T; G risk allele). Bars
represent the standard error (SE). * p,0.05; ** p,0.005.
doi:10.1371/journal.pone.0016181.g002
Fine Mapping of NRG1
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to control gene regulation, chromosome structure, and other key
functions.
Annotation and sequences of the DNA polymorphisms in the
350 kb region were downloaded from the NCBI dbSNP database
(dbSNP129). Among the 2675 polymorphisms downloaded, we
excluded 520 multiallelic variants and those known to be
monomorphic SNPs in Asians. SNPs with MAF as low as 1% in
HapMap were not excluded as we attempted to fine map the
casual variant affecting the disease, which could be quite rare in
the general population.
In order to minimize the genotyping cost, we used WCLUS-
TAG[27], an in-house developed tagging program, to identify tag
SNPs among the HapMap genotyped SNPs (r2.0.90).
For selection of SNPs without population frequencies available,
we applied a tiered approach based on their functional
significance: i) we force-included all nonsynonymous SNPs, since
presumably they have higher impact on protein structure and
function; and ii) we selected SNPs according to functional scores.
For this, we relied on two databases, Ensembl and UCSC. The
criteria for selection included accessibility to chromatin, CpG
islands associated with promoter and the degree of conservation
among species (Multiz 28-way). For each SNP, we also checked if
the allelic variation introduces potential change in predicted
transcription factor binding sites (TFBS). To this end, we used P-
MATCH[28]. We assigned a higher score to SNPs whose
variation disrupts an existing TFBS or creates a new one.
A total of 243 SNPs spanning about 350 kb of chromosome 8
(from 32.236 Mb to 32.575 Mb) were selected for genotyping.
SNP genotyping. The 243 SNPs selected were genotyped in
343 HSCR cases and in 359 controls using Sequenom technology
as previously described[29]. After removing 12 cases and 8
controls with call rate ,90%, 331 HSCR cases and 351 controls
remained for association analysis. Standard quality control criteria
for SNPs were employed, leaving a total of 207 SNPs with call rate
.95%, MAF.1% and not violating Hardy Weinberg equilibrium
(p.0.001).
Real-time assay for gene expression. Resected colon
tissues were collected from 40 HSCR patients and 21 non-
HSCR patients. No tissues were available from the rest of the
patients. All resected tissues were immediately placed in liquid
nitrogen and then stored at –80uC before analysis. Full-thickness
tissues from ganglionic portions of bowel of each HSCR patient
and colons from non-HSCR patients were used for RNA
extraction by Trizol Reagent (Life Technologies, Rockville, MD)
and converted to cDNA using an oligo (dT)15 primer and
Superscript III (Invitrogen, Carlsbad, CA). The cDNA products
equivalent to 10 ng of total RNA were used for quantitative real-
time PCR which was performed by ready-to-use TaqMan gene
expression assays from Applied Biosystems. The assay for NRG1
was Hs00247620_m1, which targets all but type 3 NRG1 SMDF
(this isoform plays a major role in myelination). Real-time qPCR
was performed in triplicate (96-well plates) on an ABI 7900
(Applied Biosystems) machine using standard thermal cycling
conditions (10 min at 95uC, 40 cycles for 15 s at 95uC, 1 min at
6uC). A standard curve was constructed for each PCR run with 10-
fold serial dilutions containing 100, 10, 1, 0.1 and 0.01 ng/mL of
cDNA from the neuroblastoma cell line HTB11. The amount of
target gene per sample was interpolated according to the standard
curves. All analyses were performed in a blinded fashion with the
laboratory operators unaware of genotyping data.
Statistical analysis. Association was assessed by means of R
and PLINK[30] using logistic regression under an additive model
and sample origin (Northern vs. Southern Chinese) was included as
a covariate to correct for population stratification.
To further evaluate the association of untyped markers tagged
by the genotyped SNPs, imputation was carried out by
MACH[31] using HapMap Phase II CHB haplotypes as
reference. As our ultimate goal here was to pinpoint the causal
variant of NRG1, increasing marker density outweighed the use of
the less dense yet more accurate Phase III panel.
We examined the effects of case-control status and NRG1
genotype on log-transformed NRG1 expression in gut via two-way
ANOVA and post-hoc test of all pair-wise differences. These
statistical analyses were done using R. All statistical tests were two-
sided, and p,0.05 was considered significant.
Supporting Information
Table S1 Characteristics of the Chinese HSCR patients
included in the NRG1 genotyping.
(DOCX)
Figure S1 Schematic representation of the 350 kb NRG1
HSCR-associated region. On the top panel, close-up of the
chromosome 8 association peak obtained in the GWAS. Middle
panel, recombination rates throughout the region (red vertical lines).
NRG1 isoforms are represented by grey lines (boxes represent
exons). Bottom line, Haploview representation of the LD in the
region (D9).
(TIF)
Figure S2 Regional map of the 5 HSCR-associated
SNPs. rs10088313, rs10094655, rs4624987, rs3884552 and
rs16879552 depicted in top green panel, from left to right.
Conservation information was given by PhastCon score for Multiz
28-way alignment for vertebrates (hg18).
(TIF)
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